Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Five-Year Risks of Systemic Complications with Biologic versus Conventional Therapy in Non-infectious Uveitis.

Ophthalmology·2026
Same author

Systemic Anemia and the Risk of Diabetic Macular Edema and Anti-VEGF Injections.

Ophthalmology. Retina·2026
Same author

Precision Medicine in Inherited Retinal Disease: Advances, Challenges, and Future Directions.

Journal of personalized medicine·2026
Same author

Dopamine-Enhancing Therapies and Risk of Neovascular AMD Conversion: A Target Trial Emulation.

American journal of ophthalmology·2026
Same author

Association between statin use and dry eye disease: A systematic review and meta-analysis.

American journal of ophthalmology·2026
Same author

Association of hydroxyurea use and sickle cell retinopathy: A systematic review and meta-analysis.

Survey of ophthalmology·2026
Same journal

Effect of key baseline disease characteristics on aflibercept 8 mg dosing interval extension: A post hoc 96-week analysis of PULSAR.

Ophthalmology. Retina·2026
Same journal

Congenital Prepapillary Vascular Loops.

Ophthalmology. Retina·2026
Same journal

Lupus Erythematosus Presenting with Ischemic Retinopathy due to Severe Anemia.

Ophthalmology. Retina·2026
Same journal

Bubble Trouble: Preventing Severe Complications after Intraocular Gas Tamponade in Vitreoretinal Surgery.

Ophthalmology. Retina·2026
Same journal

Visual Recovery After Surgery in Epiretinal Membrane Eyes with Retinal Nerve Fiber Layer Schisis and Internal Limiting Membrane Tear.

Ophthalmology. Retina·2026
Same journal

Masquerading disease of macular telangiectasia type 2 - MacTel Project Report No 11.

Ophthalmology. Retina·2026
See all related articles

Related Experiment Video

Updated: Jun 28, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Statin Intensity and the Risk of Noninfectious Uveitis.

Jawad Muayad1, Muhammad Z Chauhan1, Fahad R Butt2

  • 1Bernice and Harvey Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Ophthalmology. Retina
|June 26, 2026
PubMed
Summary
This summary is machine-generated.

High-intensity statin therapy significantly reduces the 5-year risk of noninfectious uveitis (NIU) in patients with hyperlipidemia. This protective effect is dose-dependent, with higher statin potency offering greater benefits for ocular inflammation.

Keywords:
Intraocular InflammationNoninfectious UveitisStatins

More Related Videos

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Related Experiment Videos

Last Updated: Jun 28, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Area of Science:

  • Ophthalmology
  • Cardiology
  • Pharmacology

Background:

  • Noninfectious uveitis (NIU) is a significant cause of vision impairment.
  • Statins are widely used for hyperlipidemia management.
  • The ocular effects of statin intensity are not fully understood.

Purpose of the Study:

  • To investigate the association between statin therapy intensity and the 5-year risk of incident noninfectious uveitis (NIU) in patients with hyperlipidemia.

Main Methods:

  • Retrospective, propensity score-matched cohort study using a nationwide electronic medical record network.
  • Compared high-, medium-, and low-intensity statin users against active (PPI users) and unexposed controls.
  • Propensity score matching balanced baseline characteristics; 5-year hazard ratios (HR) for NIU were calculated.

Main Results:

  • High-intensity statins significantly reduced the 5-year risk of overall NIU and anterior uveitis compared to both unexposed and active controls.
  • Medium-intensity statins showed a significant risk reduction for overall NIU and anterior uveitis against unexposed controls.
  • Low-intensity statins did not significantly alter NIU risk; negative control analyses supported findings.

Conclusions:

  • Statin therapy is associated with an intensity-dependent reduction in NIU risk.
  • High-intensity statin regimens provide the most significant and sustained protective benefit against NIU.
  • Higher statin potency may be necessary for clinically significant modulation of ocular inflammation.